PI
ABCL icon

PEAK6 Investments’s AbCellera Biologics ABCL Stock Holding History

PEAK6 Investments’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,282
Closed -$246K – 5020
2021
Q3 		$246K Buy
+12,282
New +$217K ﹤0.01% 3841
2021
Q1 		– Sell
-7,631
Closed -$307K – 4754
2020
Q4 		$307K Buy
+7,631
New +$349K ﹤0.01% 3474

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
DB
DCVC Bio Palo Alto, California $313K AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

PEAK6 Investments's ABCL Position: Q4 2021 in Review

PEAK6 Investments sold out of AbCellera Biologics (ABCL) in Q4 2021, closing a stake of 12,282 shares — an estimated $246K sold.

PEAK6 Investments first reported a position in ABCL in Q4 2020 and held it in 2 quarters. The position peaked at $307K in Q4 2020. 124 funds tracked by Wall St. Rank hold ABCL as of Q4 2021.

  • PEAK6 Investments reported no remaining AbCellera Biologics position as of Q4 2021 after selling out during the quarter.
  • PEAK6 Investments sold 12,282 AbCellera Biologics shares in Q4 2021, an estimated $246K.
  • PEAK6 Investments first reported a position in AbCellera Biologics in Q4 2020 and held it in 2 quarters.
  • PEAK6 Investments's AbCellera Biologics position peaked at $307K in Q4 2020.
  • 124 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2021.

Based on PEAK6 Investments's 13F filing for Q4 2021, filed 11 Feb 2022.